Uveitis despite adalimumab therapy in Blau syndrome.

Authors

Takeshi Takasaki, Meri Watanabe, Yuta Kawahara, Toshikatsu Kaburaki

Published in

BMJ case reports. Volume 19. Issue 10. Oct 05, 2026. Epub Oct 05, 2026.

Abstract

Blau syndrome is a rare granulomatous autoinflammatory disease caused by NOD2 mutations and characterised by dermatitis, arthritis and uveitis. We report a middle childhood boy initially diagnosed with oligoarticular juvenile idiopathic arthritis (JIA) because arthritis was the predominant early manifestation. He had papular skin lesions in infancy and periarticular swelling and tenosynovial cysts, later developed persistent arthritis and recurrent fever. Genetic testing identified a heterozygous NOD2 variant (c.1001G>A, p.Arg334Gln [R334Q]), confirming Blau syndrome. Despite ongoing methotrexate and adalimumab therapy, routine ophthalmic examination revealed unilateral anterior uveitis with iris nodules. Fundus examination showed bilateral multifocal chorioretinal lesions, and fluorescein angiography demonstrated retinal vasculitis. Ocular inflammation became quiescent after topical corticosteroid treatment and weight-based escalation of adalimumab. This case highlights that Blau syndrome may masquerade as JIA and that regular ophthalmic surveillance remains essential even during biologic therapy.

PMID:
42833844
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.